Nuvaxovid, the COVID-19 vaccine developed by Novavax, has today been granted an extension to its existing UK approval, for 12- to 17-year-olds. This extension has been authorised by the Medicines and Healthcare products Regulatory Agency.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/nMsrcGZ
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Britain approves Novavax COVID-19 vaccine Nuvaxovid for children aged between 12 and 17 years
https://ift.tt/gUV4Gmr
No comments:
Post a Comment